A Study of Suvecaltamide in Adults With Moderate to Severe Residual Tremor in Parkinson's Disease

Summary

This is a 17-week double-blind, placebo-controlled, randomized, flexible-dosing, parallel-group, multicenter study designed to evaluate the efficacy and safety of suvecaltamide for the treatment of moderate to severe residual tremor in adult participants with Parkinson's disease (PD). The target population represents participants who have tremor that is not adequately controlled by PD medications and that interferes with their activities of daily living (ADL) and/or with their performance of tasks.

Timeline

Start

2022-12-01

Primary completion

2024-10-23

Completion

2024-11-11

Drugs

Indications